Wolbachia-infected Aedes aegypti mosquitoes

PreclinicalBiologic

Wolbachia-infected Aedes aegypti mosquitoes is one of 5 biologic programs targeting Dengue. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DengueTerminated

DenguePreclinical

Terminated

Competition

Competitive Landscape

7 competitors in Dengue

#DrugCompanyPhaseTrials

Lagevrio

Merck & Co.

Phase 2

1 2

Rden2δ30-7169

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 3

Biological

NNational Environment Agency, Singapore

Preclinical

2 4

Wolbachia-infected Aedes aegypti mosquitoes

GGadjah Mada University

Preclinical

1 5

Emetine Hydrochloride

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dengue1 trial

Applying Wolbachia to Eliminate Dengue

Terminated·GGadjah Mada University·N/A·NCT03055585·8,173 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Wolbachia-infected Aedes aegypti mosquitoes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Wolbachia-infected Aedes aegypti mosquitoes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Wolbachia-infected Aedes aegypti mosquitoes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gadjah Mada University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GGadjah Mada University

Wolbachia-infected Aedes aegypti mosquitoes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dengue1 trial

References

Drug Info

Quick Facts

Related News